Virtually all the one-time toolkit/service companies are now setting their sights on migrating downstream, each in its own way. ArQule Inc. is aiming to become an IND engine, based on a foundation in primary lead screening to increase the hit rate of compounds. Last week the company extended its 1999 deal with Pfizer Inc. in the hopes of adding value to its own platform.

Under the deal, which extends the alliance through 2008, ARQL will provide expanded lead generation capabilities and will transfer technology related to its library design and informatics platform, which the pharma company will use on a non-exclusive basis. The companies will